ArticleObesity surgery2026
Comparative Effectiveness of Sleeve Gastrectomy and One-Anastomosis Gastric Bypass on Cardiovascular Disease Risk: Insights from a Prospective Cohort Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic comparison of triglyceride-glucose (TYG)-index with other mortality predictive models in obese patients with different mortality rates.Cardiovascular diabetology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study compares the effectiveness of sleeve gastrectomy (SG) and one-anastomosis gastric bypass (OAGB) on the predicted 10-year atherosclerotic cardiovascular disease (ASCVD) risk and identifies key factors influencing postoperative (post-op) changes in ASCVD risk.
methodsThis prospective cohort study assessed the 10-year ASCVD risk in patients undergoing SG or OAGB between 2013 and 2023 using the ACC/AHA ASCVD Risk Estimator. In addition to the baseline assessment, the risk score was evaluated at 6, 12, 24, 36, and 48 months post-op. Longitudinal analysis tracked changes in ASCVD risk, and regression models identified individual and combined factors influencing these changes.
resultsThe analysis enrolled 1397 individuals (mean age 50.1 years, 87.9% female), including 952 SG and 445 OAGB participants. Following adjustments, the 10-year ASCVD risk significantly reduced post-op with no observed differences between the surgical groups. Positive associations with risk reduction were found for baseline risk, total cholesterol (TC), type 2 diabetes mellitus (T2DM), triglycerides (TG), systolic blood pressure (SBP), fasting plasma glucose (FPG), and estimated glomerular filtration rate (eGFR). In contrast, age, triglyceride-glucose (TyG) index, hemoglobin A1c (HbA1c), male sex, smoking, and high-density lipoprotein cholesterol (HDL-C) demonstrated negative associations with ASCVD risk reduction.
conclusionMetabolic and bariatric surgery significantly reduced the 10-year ASCVD risk, with comparable outcomes between SG and OAGB. Key determinants influencing the 10-year ASCVD risk reduction included baseline risk score, age, TC, T2DM, TyG index, TG, HbA1c, SBP, sex, FPG, smoking, HDL-C, and eGFR.
Indexed as
Identifiers
41201757What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.